Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalutrafusp alfa - Agenus

Next Previous
Drug Profile

Dalutrafusp alfa - Agenus

Alternative Names: AGEN-1423; Anti-CD73-TGFβ-Trap Bifunctional Antibody; GS-1423; TME conditioning anti-CD73/TGFβ TRAP

Latest Information Update: 17 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; Gilead Sciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 Jan 2026 Efficacy and adverse events data from a phase II trial in Pancreatic ductal adenocarcinoma presented at the 2026 Gastrointestinal Cancers Symposium (GCS-2026)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in USA (Parenteral)
  • 08 Aug 2024 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT05632328)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top